References
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104. https://doi.org/10.1093/eurheartj/ehy339
- Conen D, Aeschbacher S, Thijs L, et al. Age-specific differences between conventional and ambulatory daytime blood pressure values. Hypertension 2014;64:1073-1079. https://doi.org/10.1161/HYPERTENSIONAHA.114.03957
- Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (systolic blood pressure intervention trial). Hypertension 2018;71:848-857. https://doi.org/10.1161/HYPERTENSIONAHA.117.10479
- Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 1991;18:67-71. https://doi.org/10.1161/01.HYP.18.1.67
- Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. https://doi.org/10.1056/NEJMoa0801369
- JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115-2127. https://doi.org/10.1291/hypres.31.2115
- SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116. https://doi.org/10.1056/NEJMoa1511939
- Hughes TM, Sink KM. Hypertension and its role in cognitive function: current evidence and challenges for the future. Am J Hypertens 2016;29:149-157. https://doi.org/10.1093/ajh/hpv180
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
- Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068. https://doi.org/10.1016/S0140-6736(15)00257-3
- Kim HC, Oh SM. Noncommunicable diseases: current status of major modifiable risk factors in Korea. J Prev Med Public Health 2013;46:165-172. https://doi.org/10.3961/jpmph.2013.46.4.165